Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia
Pfeifer, H, Wassmann, B, Bethge, W, Dengler, J, Bornhäuser, M, Stadler, M, Beelen, D, Vucinic, V, Burmeister, T, Stelljes, M, Faul, C, Dreger, P, Kiani, A, Schäfer-Eckart, K, Schwerdtfeger, R, Lange, E, Kubuschok, B, Horst, H A, Gramatzki, M, Brück, P, Serve, H, Hoelzer, D, Gökbuget, N, Ottmann, O G
Published in Leukemia (01.06.2013)
Published in Leukemia (01.06.2013)
Get full text
Journal Article
Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany
Hofheinz, R, Clouth, J, Borchardt-Wagner, J, Wagner, U, Weidling, E, Jen, M H, Brück, P
Published in BMC cancer (06.12.2016)
Published in BMC cancer (06.12.2016)
Get full text
Journal Article
A heuristic algorithm for a single vehicle static bike sharing rebalancing problem
Cruz, Fábio, Subramanian, Anand, Bruck, Bruno P., Iori, Manuel
Published in Computers & operations research (01.03.2017)
Published in Computers & operations research (01.03.2017)
Get full text
Journal Article
Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph ALL) during imatinib treatment
Scheuring, U J, Pfeifer, H, Wassmann, B, Brück, P, Gehrke, B, Petershofen, E K, Gschaidmeier, H, Hoelzer, D, Ottmann, O G
Published in Leukemia (01.09.2003)
Published in Leukemia (01.09.2003)
Get full text
Journal Article
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
PFEIFER, H, LANGE, T, WUNDERLE, L, SERVE, H, BRÜCK, P, SCHMIDT, A, HOELZER, D, OTTMANN, O. G, WYSTUB, S, WASSMANN, B, MAIER, J, BINCKEBANCK, A, GIAGOUNIDIS, A, STELLJES, M, SCHMALZING, M, DÜHRSEN, U
Published in Leukemia (01.07.2012)
Published in Leukemia (01.07.2012)
Get full text
Journal Article
Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment
BRÜCK, P, MOUSSET, S, BÖHME, A, HOELZER, D, ATTA, J
Published in International journal of hematology (01.07.2007)
Published in International journal of hematology (01.07.2007)
Get full text
Journal Article
1503TiP A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50
Awad, M.M., Hao, Y., Li, S., Kaul, M., Seebach, F., Goncalves, P., Brück, P., Rietschel, P.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
1196TiP LuCa-MERIT-1: First-in-human, open label, phase I dose confirmation trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer
Forde, P.M., Atmaca, A., Brück, P., Munshi, N., Kaczorowska, M.A., Schell, T., Türeci, Ö., Sahin, U.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
Minimizing CO2 emissions in a practical daily carpooling problem
Bruck, Bruno P., Incerti, Valerio, Iori, Manuel, Vignoli, Matteo
Published in Computers & operations research (01.05.2017)
Published in Computers & operations research (01.05.2017)
Get full text
Journal Article
The Static Bike Sharing Rebalancing Problem with Forbidden Temporary Operations
Bruck, Bruno P, Cruz, Fabio, Iori, Manuel, Subramanian, Anand
Published in Transportation science (01.05.2019)
Published in Transportation science (01.05.2019)
Get full text
Journal Article
PD-008 Adding ramucirumab to second-line irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) treatment for metastatic colorectal carcinoma (mCRC): resource utilization data from RAISE, a global, randomized, double-blind, multicenter phase 3 study
Kisro, J., Cohn, A., Yoshino, T., Van Cutsem, E., Hegewisch-Becker, S., Kullmann, F., Brück, P., Liepa, A., Yang, L., Nasroulah, F., Tabernero, J.
Published in Annals of oncology (01.06.2016)
Published in Annals of oncology (01.06.2016)
Get full text
Journal Article
Adding Ramucirumab To Second-Line Irinotecan, 5-Fluorouracil and Folinic Acid (Folfiri) Treatment for Metastatic Colorectal Carcinoma (Mcrc): Resource Utilization Data from Raise, A Global, Randomized, Double-Blind, Multicenter Phase 3 Study
Brück, P, Kisro, J, Cohn, AL, Yoshino, T, Van Cutsem, E, Hegewisch-Becker, S, Kullmann, F, Liepa, AM, Yang, L, Nasroulah, F, Tabernero, J
Published in Value in health (01.10.2017)
Published in Value in health (01.10.2017)
Get full text
Journal Article
PCN1 - Adding Ramucirumab To Second-Line Irinotecan, 5-Fluorouracil and Folinic Acid (Folfiri) Treatment for Metastatic Colorectal Carcinoma (Mcrc): Resource Utilization Data from Raise, A Global, Randomized, Double-Blind, Multicenter Phase 3 Study
Brück, P, Kisro, J, Cohn, AL, Yoshino, T, Van Cutsem, E, Hegewisch-Becker, S, Kullmann, F, Liepa, AM, Yang, L, Nasroulah, F, Tabernero, J
Published in Value in health (01.10.2017)
Published in Value in health (01.10.2017)
Get full text
Journal Article
155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT
Klinghammer, K., Saba, N.F., Castelluci, E., Colevas, A.D., Rutkowski, T., Greil, R., Thurner, D., Müller-Richter, U., Di Giacomo, A.M., Grewal, J., Ottensmeier, C.H.H., Atasoy, A., Shpyro, S., Brück, P., Dias, J., Ganser, C., Türeci, Ö., Sahin, U.
Published in Immuno-oncology technology (01.12.2022)
Published in Immuno-oncology technology (01.12.2022)
Get full text
Journal Article